Antithrombotic Therapy: An Abbreviated Reference for Clinicians

Archives of Internal Medicine

Volumn 155, Issue 2, 1995, Pages 149-161

  Becker, Richard C ^a   Ansell, Jack ^b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b BOSTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANISTREPLASE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; DEXTRAN; DEXTRAN 40; DIHYDROERGOTAMINE; DIPYRIDAMOLE; FISH OIL; HEPARIN; HIRUDIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; MEVINOLIN; OMEGA 3 FATTY ACID; STREPTOKINASE; TICLOPIDINE; VITAMIN K GROUP; WARFARIN;

ACUTE HEART INFARCTION; ANGINA PECTORIS; ANTICOAGULANT THERAPY; BLEEDING; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DILATATION; CORONARY ARTERY DISEASE; DRUG CONTRAINDICATION; DRUG INDUCED DISEASE; FIBRINOLYTIC THERAPY; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HEART VALVE PROSTHESIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MITRAL VALVE DISEASE; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PARTIAL THROMBOPLASTIN TIME; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; PROTHROMBIN TIME; REVIEW; STROKE; SUBCUTANEOUS DRUG ADMINISTRATION; SURGICAL PATIENT; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; VALVULAR HEART DISEASE; VEIN THROMBOSIS;

CLINICAL TRIALS; HUMAN; THROMBOLYTIC THERAPY; THROMBOSIS;

EID: 0028891769     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.1995.00430020034005     Document Type: Article

References (11)

1. Dalen JE, Hirsh J, eds. Third ACCP Consensus Conference on Antithrombotic Therapy. Chest. 1992;102:303S-549S.
2. Raschke RA, Reilly BM, Guidtry JR, Fontanta JR, Srinvivas S. A weight-based heparin dosing nomogram compared with a ‘standard care’ nomogram. Ann Intern Med. 1993;119:874-881.
3. Simoons ML, Maggioni AP, Knatterud G, et al. Individual risk assessment for intracranial haemorrhage during thrombolytic therapy. Lancet. 1993; 342:1523-1528.
4. Turpie AGG, Gent M, Laupacis A, et al. A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med. 1993;329:524-525.
5. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke. Lancet. 1993;342:1255-1262.
6. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet. 1994; 343:687-691.
7. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673-682.
8. O'Connor CM, Meese R, Carney R, et al, from the Duke University Clinical Cardiology Study (DUCCS) 1. A randomized trial of intravenous heparin conjunction with anistreplase (APSAC) in acute myocardial infarction. J Am Coll Cardiol. 1994;23:11-18.
9. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81-106.
10. Pantrano C. Aspirin as an antiplatelet drug. N Engl J Med. 1994;330:1287-1294.
11. Canon CP, McCabe CH, Henry TD, et al, for the TIMI 5 Investigators. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the TIMI 5 trial. J Am Coll Cardiol. 1994;23:993-1003.